US company develops promising male contraceptive

lepoint.fr (French)

A new non-hormonal male contraceptive, YCT-529, shows promising results in early human trials, potentially offering men an alternative to condoms and vasectomy. Developed by YourChoice Therapeutics, the molecule inhibits sperm production by blocking a vitamin A metabolite. Animal studies demonstrated effectiveness and reversibility, with initial human trials focusing on safety appearing reassuring. Despite encouraging scientific data, long-term safety is unconfirmed, and the pharmaceutical industry remains hesitant to invest in male contraceptive development due to perceived risks and market concerns.


With a significance score of 3.9, this news ranks in the top 4.9% of today's 24143 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


US company develops promising male contraceptive | News Minimalist